A study indicated that metastatic renal cell carcinoma patients with thrombocytosis were more likely to develop drug resistance against anti-VEGF treatment than patients with normal platelet count.[37] Considering the promising prospect anti-VEGF therapies have in gastric cancer treatment, thrombocytosis could be a predictive factor for the efficiency of anti-VEGF therapies in GC patients. The gene discussed is VEGFA; the disease is Thrombocytosis.